Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cencora, Inc.COR · Entity 2994 | Director | March 05, 2026 | March 09, 2026 |
| DuPont de Nemours, Inc.DD · Entity 3297 | Director | April 28, 2021 | April 30, 2021 |
| INTERNATIONAL FLAVORS & FRAGRANCES INCIFF · Entity 3234 | Chief Executive Officer | March 01, 2024 | March 06, 2024 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Pres ? Human Health | May 04, 2021 | November 04, 2021 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cencora, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,724 |
Reported balance
After 2026-03-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 557 · Balance 1,724 F1: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant.
DuPont de Nemours, Inc.
Report date April 28, 2021 · Filed April 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,034.4895 |
Reported balance
After 2021-04-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-04-28 · Grant · Acquired 2,207 · Balance 8,034.4895 F1: Includes acquisition of shares pursuant to dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes acquisition of shares pursuant to dividend reinvestment.
INTERNATIONAL FLAVORS & FRAGRANCES INC
Report date March 01, 2024 · Filed March 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,847 |
Ending reported balance
After 2024-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-01 · Exercise / conversion · Acquired 1,324 · Balance 2,170 F1: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on March 1, 2022. F2: The RSUs convert to Common Stock on a one-for-one basis. Row 2 · 2024-03-01 · Tax withholding · Disposed 323 · Balance 1,847 F3: Reflects shares withheld for taxes payable upon the vesting of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 33,682 |
Reported balance
After 2024-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-01 · Exercise / conversion · Disposed 1,324 · Balance 33,682 F2: The RSUs convert to Common Stock on a one-for-one basis. F1: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on March 1, 2022. F4: The RSUs vested on March 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on March 1, 2022.
F2: The RSUs convert to Common Stock on a one-for-one basis.
F3: Reflects shares withheld for taxes payable upon the vesting of RSUs.
F4: The RSUs vested on March 1, 2024.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Merck & Co., Inc.
Report date May 04, 2021 · Filed November 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 39,479 |
Reported balance
After 2021-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-04 · Grant · Acquired 39,479 · Balance 39,479 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in one installment on 5/4/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in one installment on 5/4/2024.
Revolution Medicines, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,929 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 1,191 · Balance 10,929 F1: Includes 4,080 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $162.99 · Expires 2036-06-18 | Direct | 3,127 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 3,127 · Balance 3,127 F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 4,080 restricted stock units.
F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2020 Filed May 6, 2020 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,848 | $76.86 | $142,037.28 |
DisclosureSEC source: 0001127602-20-015658 · form4.xml · nonDerivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,763.106 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 05, 2020 Filed May 6, 2020 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,752 | $76.86 | $288,378.72 |
DisclosureSEC source: 0001127602-20-015658 · form4.xml · nonDerivative · entry 3 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,611.106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015658 · form4.xml · derivative · entry 6 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906 Underlying: Common Stock · 1,904 shares Expires 2021-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 938 | $77.67 | $72,854.46 |
DisclosureSEC source: 0001127602-20-015658 · form4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,859.106 Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,904 | $77.67 | $147,883.68 |
DisclosureSEC source: 0001127602-20-015658 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,797.106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 75,514 | $0.00 Strike: $77.67 | $0.00 |
DisclosureSEC source: 0001127602-20-015441 · form4.xml · derivative · entry 3 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,514 Underlying: Common Stock · 75,514 shares Expires 2030-04-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 4,905 | $76.56 | $375,526.80 |
DisclosureSEC source: 0001127602-20-009129 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,297.991 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/17. Performance shares were paid out at 137 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2019. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,287 | $85.10 | $194,623.70 |
DisclosureSEC source: 0001225208-19-014014 · doc4.xml · derivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,575 Underlying: Common Stock · 2,287 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,127 | $85.10 | $95,907.70 |
DisclosureSEC source: 0001225208-19-014014 · doc4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,904.968 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-014014 · doc4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,031.968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:33 UTC | DuPont de Nemours, Inc. DD · Entity 3297 | GrantCommon Stock | 2,240 | $76.10 | $170,464.00 |
DisclosureSEC source: 0001666700-19-000049 · edgar.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,240 F1 · balance_after: Includes unvested RSUs. Read SEC document |
| May 10, 2019 Filed May 13, 2019 21:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,389 | $78.33 | $343,790.37 |
DisclosureSEC source: 0001104659-19-028974 · a4.xml · derivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,389 shares Expires 2019-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 10, 2019 Filed May 13, 2019 21:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 2,162 | $78.33 | $169,349.46 |
DisclosureSEC source: 0001104659-19-028974 · a4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,831.087 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 10, 2019 Filed May 13, 2019 21:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-028974 · a4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,993.087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2019 Filed May 9, 2019 22:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001104659-19-028305 · a4.xml · derivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,876 Underlying: Common Stock · 25,000 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in three equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| May 07, 2019 Filed May 9, 2019 22:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 25,000 | $77.73 | $1,943,182.50 |
DisclosureSEC source: 0001104659-19-028305 · a4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,604.087 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.6400 to $77.8200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2019 Filed May 9, 2019 22:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 25,000 | $39.29 | $982,250.00 |
DisclosureSEC source: 0001104659-19-028305 · a4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,604.087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2019 Filed May 7, 2019 23:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,904 | $80.00 | $152,320.00 |
DisclosureSEC source: 0001104659-19-027579 · a4.xml · derivative · entry 5 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,810 Underlying: Common Stock · 1,904 shares Expires 2021-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2019 Filed May 7, 2019 23:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 938 | $80.00 | $75,040.00 |
DisclosureSEC source: 0001104659-19-027579 · a4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,604.087 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2019 Filed May 7, 2019 23:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027579 · a4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,542.087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 50,808 | $0.00 Strike: $80.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027579 · a4.xml · derivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,808 Underlying: Common Stock · 50,808 shares Expires 2029-05-02 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 4,017 | $80.38 | $322,886.46 |
DisclosureSEC source: 0001225208-19-003890 · doc4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,188.725 F1 · shares: Distrubtion of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/16. Performance shares were paid out at 126 percent of target awards. Includes dividends accured over the three-year performance period ending December 31, 2018. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.